Search criteria | ||||
Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions | ||||
Oriol Sola- Morales (1), Lesley H. Curtis (2), Julien Heidt (3),*, Laura Walsh (4), Deborah Casso (5),?, Susan Oliveria (6),?, Patrick Saunders- Hastings (7), Yufei Song (8),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9) | ||||
(1) Fundació Health Innovation Technology Transfer and International, University of Catalonia, Barcelona, Spain; (2) Duke Clinical Research Institute, Durham, North Carolina, USA; (3) IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; (4) IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; (5) IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; (6) IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; (7) Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; (8) IQVIA, Epidemiology and Drug Safety Practice, Beijing, China; (9) Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA | ||||
Clinical pharmacology and therapeutics vol. 114,2 (2023): 325-355. doi:10.1002/cpt.2914 |
||||
, Article | ||||
, Europe, USA | ||||
Abstract: https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2914 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory | 2023 | English | , Review | |
Regulatory and HTA Considerations for Development of Real- World Data Derived External Controls | ||||
Lesley H. Curtis (1), Oriol Sola-Morales (2), Julien Heidt (3),*, Patrick Saunders- Hastings (4), Laura Walsh (5), Deborah Casso (6),?, Susan Oliveria (7),?, Tiffany Mercado (3), Robbert Zusterzeel (3),?, Rachel E. Sobel (8), Jessica J. Jalbert (9), Vera Mastey (9), James Harnett (9) and Ruben G. W. Quek (9) | ||||
1Duke Department of Population Health Sciences and Duke Clinical Research Institute, Durham, North Carolina, USA; 2Fundació HiTT and Universitat Internacional de Catalunya (UIC), Barcelona, Spain; 3IQVIA, Regulatory Science and Strategy, Falls Church, Virginia, USA; 4Epi Excellence LLC, Garnet Valley, Pennsylvania, USA; 5IQVIA, Epidemiology and Drug Safety Practice, Boston, Massachusetts, USA; 6IQVIA, Epidemiology and Drug Safety Practice, Seattle, Washington, USA; 7IQVIA, Epidemiology and Drug Safety Practice, New York, New York, USA; 8Regeneron Pharmaceuticals Inc., Pharmacoepidemiology, Tarrytown, New York, USA; 9Regeneron Pharmaceuticals Inc., Health Economics & Outcomes Research, Tarrytown, New York, USA. | ||||
Clin Pharmacol Ther, 114: 303-315. https://doi.org/10.1002/cpt.2913 |
||||
, Article | ||||
, USA | ||||
Abstract: https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.2913 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Methodology, Regulatory | 2023 | English | , Review | |
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis | ||||
Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó | ||||
"a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit�e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany" | ||||
, Article | ||||
, Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey | ||||
Abstract: https://www.tandfonline.com/doi/full/10.1080/03007995.2023.2256220 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders | 2023 | English | , clinical setting: Secondary care, Epidemiological study, Population Based Study | |
The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making | ||||
Paul Cottu 1, Scott David Ramsey 2, Oriol Solà -Morales 3, Patricia A Spears 4, Lockwood Taylor 5 | ||||
1Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm, 75005, Paris, France. Electronic address: paul.cottu@curie.fr. 2Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, M2-B232, Seattle, WA, 98155, USA. Electronic address: sramsey@fredhutch.org. 3Health Innovation Technology Transfer Foundation, Aragó 60, E-08015, Barcelona, Spain. Electronic address: osola@fhitt.org. 48605 Carolingian Court, Raleigh, NC, 27615, USA. Electronic address: paspears88@gmail.com. 5Epidemiology, Real World Solutions at IQVIA, 4820 Emperor Boulevard, Durham, NC, 27703, USA. Electronic address: lockwood.taylor@iqvia.com. | ||||
Breast. 2021 Dec 22;61:118-122. doi: 10.1016/j.breast.2021.12.015. |
||||
, Article | ||||
, France, Italy, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/34959093/ | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Drug safety, Oncology, Regulatory | 2022 | English | , Review | |
Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal | ||||
Max Schlueter, Amélie Beaudet, Evan Davies, Binu Gurung, Andreas Karabis | ||||
IQVIA, 210 Pentonville Road, London, N1 9JY; IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, Netherlands; Department of Statistical Science, University College London, London, WC1E 6BT, UK. | ||||
, Article | ||||
Abstract: https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-020-01241-4 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Methodology, Rare Diseases | 2020 | English | , Literature Review, Review | |
Cost-utility model for 2nd generation treatment of chronic HCV in general population: impact of EASL recommendations in 2016 and 2018 | ||||
Natàlia Pascual-Argenté (1,2); Carlos Crespo (1,3); Laura Planellas (4); Míriam Solozabal (4), Núria Perulero (4); Jaume Puig-Junoy (1,2) | ||||
(1) UPF Barcelona School of Management; (2) Dept. Economía y Empresa – CRES UPF; (3) Universitat de Barcelona; (4) HEOR-RWE, IQVIA Spain | ||||
XXXIX Jornadas de Economía de la Salud. Albacete, 12 al 14 de junio de 2019 |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/pdfs/Jornadas_AES_2019-Libro_abstracts.pdf | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Infectious disease | 2019 | Spanish | , Clinical setting: hospital, Cost effectiveness | |
Assessing the Outcomes for Orphan Status or Accelerated Assessment EMA Approved Medicines: A Comparison of Health Technology Assessment in Denmark, Finland, Norway and Sweden | ||||
Falla, Edel; Pitcher, Ashley; Acs, Annabel; Heller, Vincent; Zhang, Rongrong | ||||
IQVIA, Real-World Insights, London, LON, UK IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Copenhagen, Denmark IQVIA, Real-World Insights, Solna, AB, Sweden IQVIA, Real-World Insights, Stockholm, Sweden | ||||
ISPOR Europe 2019, November 5, 2019, Copenhagen, Denmark |
||||
, Poster | ||||
, Denmark, Finland, Nordic, Norway, Sweden | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(19)34089-6/fulltext?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301519340896%3Fshowall%3Dtrue#%20 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2019 | English | , Review | |
LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION. | ||||
Allou A*, Carette J*, Minacori R*, Touahmia S*, Bourguignon S*, Troubat A*, Maurel F* | ||||
IQVIA France - RWI | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Hematology | 2018 | English | , Cost effectiveness, Market impact, Review | |
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE. | ||||
Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles | ||||
RWI IQVIA France | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases | 2018 | English | , Cost effectiveness, Pricing & Reimbursement, Willingness to pay | |
ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN France | ||||
Vasilescu L., Faller M., Allou A. | ||||
IQVIA France - RWI | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Methodology | 2018 | English | , Literature Review, Public Health, Review | |
A COST-EFFECTIVENESS ANALYSIS COMPARING THE ORIGINATOR RECOMBINANT HUMAN ALFA TO THEIR BIOSIMILARS FOLLITROPIN ALFA FOR THE TREATMENT OF INFERTILITY. | ||||
Ravonimbola H(1), Petrica N (1), Maurel F(1), Murphy C(2), Doré C(2), Fresneau L(2), | ||||
(1) QuintilesIMS, Paris France (2) Merck Serono, France | ||||
ISPOR 2017 |
||||
, Poster | ||||
, France | ||||
Abstract: https://www.valueinhealthjournal.com/article/S1098-3015(17)31033-1/fulltext | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2017 | English | , Cost effectiveness, Literature Review, Randomised controlled trial | |
HEALTH-ECONOMICS EVALUATIONS IN FRANCE, ENGLAND, CANADA AND AUTRALIA: COMPARISON OF METHODOLOGIES AND IMPACT ON DRUGS | ||||
Bucher D*, Abalan M-E*, Allou A*, Dumon L*, Vialard L *, Troubat A*, Maurel F* | ||||
IQVIA France - RWI | ||||
ISPOR 2017 |
||||
, Poster | ||||
, Australia, Canada, France, UK | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2017 | English | , Cost effectiveness, Literature Review, Pricing & Reimbursement, Review | |
RiGOR: a prospective observational study comparing the effectiveness of treatment strategies for open-angle glaucoma. | ||||
Coleman AL1,2, Lum FC1, Velentgas P3, Campion D3, Su Z3, Gliklich RE4; RiGOR Study Group. | ||||
1H. Dunbar Hoskins Jr, MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 2Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA 02139, USA. | ||||
Journal of Comparative Effectiveness. Jan 2016; 5(1), 65-78 |
||||
, Article | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26690903 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2016 | English | , Observational study, Prospective study, RWLPR (Real-World Late Phase Research-quintiles | |
Impact of treatment strategies for open angle glaucoma on intraocular pressure: the RiGOR study | ||||
Coleman AL1,2, Lum FC2, Velentgas P3, Su Z3, Gliklich RE4; RiGOR Study Group. | ||||
1Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 2H Dunbar Hoskins, Jr MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA 02139, USA. 4Massachusetts Eye & Ear & Harvard Medical School, Boston, MA 02114, USA. | ||||
J Comp Eff Res. 2016 Jan;5(1):87-98 |
||||
, Article | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/26691269 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2016 | English | , Observational study, Prospective study | |
Quality of life and visual acuity outcomes in the RiGOR study | ||||
Coleman AL1,2, Lum FC1, Gliklich RE3, Velentgas P4, Su Z4; RiGOR Study Group. | ||||
1H Dunbar Hoskins, Jr MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 2Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 3Massachusetts Eye & Ear Infirmary & Harvard Medical School, Boston, MA 02114, USA. 4Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, 201 Broadway #5, Cambridge, MA 02139, USA. | ||||
J Comp Eff Res. 2016 Jan;5(1):99-111. |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2016 | English | , Observational study, Prospective study | |
Practice patterns and treatment changes for open-angle glaucoma: the RiGOR study. | ||||
Coleman AL1,2, Lum FC2, Velentgas P3, Su Z3, Gliklich RE4; RiGOR Study Group. | ||||
1Jules Stein Eye Institute, David Geffen School of Medicine & Fielding School of Public Health, University of California, Los Angeles, CA 90095, USA. 2H Dunbar Hoskins Jr, MD Center for Quality Eye Care, Foundation of the American Academy of Ophthalmology, 655 Beach Street, San Francisco, CA 94109, USA. 3Outcome DEcIDE Center, Quintiles Real World & Late Phase Research, Cambridge, MA, 02139. 4Massachusetts Eye & Ear Infirmary & Harvard Medical School, Boston, MA 02114, USA | ||||
J Comp Eff Res. 2016 Jan;5(1):79-85. |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2016 | English | , Observational study, Prospective study | |
How market access will play out | ||||
Bosco j, Dreyer N | ||||
Quintiles Real World and late phase research | ||||
Managed healthcare executive |
||||
Abstract: Managedhealthcareexecutive.com | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2016 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis. | ||||
Mack CD1, Brookhart MA, Glynn RJ, Meyer AM, Carpenter WR, Sandler RS, Stürmer T. | ||||
Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC | ||||
Epidemiology. 2015 Sep;26(5):690-9. |
||||
, Article | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Oncology | 2015 | English | , Retrospective database analysis | |
Best Methods to Get Your Comparative Effectiveness Paper Cited: How GRACE Helps. | ||||
Dreyer NA, Bryant A, Velentgas P, Su Z. | ||||
Quintales real world and late phase research | ||||
Pharmacoepidemiol Drug Saf 2015; 24(S1):360 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2015 | English | , Review, RWLPR (Real-World Late Phase Research-quintiles | |
Generating Real-world Safety and Effectiveness Evidence for Biosimilars: Current Issues and Methodological Considerations | ||||
Bosco JL, Dreyer NA, Neyarapally G, Brown JS. | ||||
Quintiles real world and late phase research | ||||
Pharmacoepidemiol Drug Saf 2015; 24(S1):416. |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2015 | English | , Methodology, Review, RWLPR (Real-World Late Phase Research-quintiles | |
Comparing Three-way and Pairwise Propensity Score Matching Approaches for Analyses of a Real-world Comparative Effectiveness Study of Glaucoma Therapies (RiGOR). | ||||
Velentgas P, Bosco JLF, Franke KM, Coleman AL, Lum FC, Gliklich R, Park J, Su Z. | ||||
Quintiles real world and late phase research | ||||
Pharmacoepidemiol Drug Saf 2015; 24(S1):217 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2015 | English | , Methodology, RWLPR (Real-World Late Phase Research-quintiles | |
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. | ||||
Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14. | ||||
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2Department of Rheumatology, CHU Strasbourg, Strasbourg, France. 3University of Cologne, Cologne, Germany. 4L Sacco University Hospital, Milan, Italy. 5University of Montreal, Montreal, Canada. 6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. 7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico. 8Department of Rheumatology, University of Liverpool, Liverpool, UK. 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 10Hellenic Foundation for Rheumatological Research, Athens, Greece. 11Quintiles, Rockville, Maryland, USA. 12F Hoffmann-La Roche Ltd, Basel, Switzerland. 13Genentech Inc, San Francisco, California, USA. 14University Hospital of Geneva, Geneva, Switzerland. | ||||
Ann Rheum Dis. 2015 Jun;74(6):979-84 |
||||
, Article | ||||
, Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431330/ | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Rheumatology | 2015 | English | , Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles | |
Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain. | ||||
Gasche D1, Restovic G1, Casado V2, RamÃrez-Boix P3, MartÃnez Lopez J3 | ||||
1IMS Health, Barcelona, Spain; 2Mataro Hospital, Mataro, Barcelona, Spain; 3Biogen, Madrid, Spain | ||||
Value in Health. Volume 18, Issue 7, November 2015, Page A755 |
||||
, Abstract | ||||
, Spain | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S1098301515050123?via%3Dihub | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Neurological disorders | 2015 | English | , Clinical setting: hospital, Cost effectiveness, Literature Review | |
Comparative Effectiveness Research (CER) of Treatments for Advanced Melanoma in Europe Using Existing Real-World Data Sources: A Feasibility Assessment | ||||
Daumont MM, Juuti R, Hoeller C, Zagorska A, Mertano E, Korhonen P | ||||
Worldwide Health Economics & Outcomes Research, Bristol-Myers Squibb, Rueil-Malmaison, France | ||||
Pigment Cell & Melanoma Research (2015) 28 (6), pp. 753-826 |
||||
, Abstract | ||||
, Europe | ||||
Abstract: https://onlinelibrary.wiley.com/doi/epdf/10.1111/pcmr.12419 | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Oncology | 2015 | English | , Literature Review, Review | |
Use of the GRACE checklist for rating the quality of observational comparative effectiveness research | ||||
Dreyer NA, Bryant A, Su Z, Velentgas P. | ||||
Quintiles real world and late phase research | ||||
Value in Health Nov 2014; 7(17): A732 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2014 | English | , Review, RWLPR (Real-World Late Phase Research-quintiles | |
Using real-world data for outcomes research and comparative effectiveness studies. Advantage Business Media | ||||
Mack C, Lang K. | ||||
Quintiles real world and late phase research | ||||
Drug Discovery & Development. Nov 2014 |
||||
, Article | ||||
Abstract: http://www.dddmag.com/article/2014/11/using-real-world-data-outcomes-research-and-comparative-effectiveness-studies | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2014 | English | , Review, RWLPR (Real-World Late Phase Research-quintiles | |
A framework for creating standardized outcome measures for patient registries. | ||||
Gliklich RE1, Leavy MB, Karl J, Campion DM, Levy D, Berliner E. | ||||
Quintiles Real World and late phase research | ||||
Journal Comparative Effectiveness Research. 2014 Sep;3(5):473-80 |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Guidelines and Recommendations for comparative effectiveness research methods | ||||
Noh E, Dreyer N, Ahn J | ||||
Quintiles Real World and late phase research | ||||
Pharmacoepidemiology Drug Safety |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. | ||||
Dreyer NA1, Velentgas P, Westrich K, Dubois R. | ||||
Quintiles Real World and late phase research | ||||
J Manag Care Spec Pharm. 2014 Mar;20(3):301-8. |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2014 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Developing a Protocol for Observational Comparative Effectiveness Research. A User’s Guide. | ||||
Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds. | ||||
AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and Quality. January 2013. |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , Review, RWLPR (Real-World Late Phase Research-quintiles | |
Using observational studies for comparative effectiveness: finding quality with GRACE. | ||||
Dreyer NA1. | ||||
Quintiles Real World and late phase research | ||||
J Comp Eff Res. 2013 Sep;2(5):413-8 |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Comparing propensity score estimation using logistic regression and generalized boosted regression in a real-world comparative effectiveness study of glaucoma therapies | ||||
Bosco JLF, Franke K, Coleman AL, Lum FC, Gliklich R, Su Z, Velentgas P | ||||
Quintiles Real World and Late phase research | ||||
29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, August 2013 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Introducing the encepp working group (WG) on health technology assessment (HTA): Enhancing the generation of additional evidence for HTA processes | ||||
Sinclair, M., Lis, Y., Van Engen, A., Van Ganse, E., Autier, P., Daumer, M., Ehrenstein, V., Qizilbash, N., Méndez, I., Engel, P., Bergman, U., Fusco, D., Pasterk, M., Postma, M. J., Smulders, M., Van Staa, T., Pariente, A., Ruether, E., Toussi, M., Moore, N., Meyer, F. & Prieto, L | ||||
Quintiles real World and late phase research, IMS RWE | ||||
ISPOR 16th Annual European Congress, Dublin, Ireland, November 2013 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
There but for GRACE? A Validated Screening Tool for Quality Observational Studies of comparative effectiveness | ||||
Dreyer NA, Velentgas P, Westrich K, Dubois, RW | ||||
Quintiles Real World and late phase Research | ||||
Research on Methods, Databases & Management Methods Section Winner |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Registry of Patient Registries (RoPR): Advancing Registries for Comparative Effectiveness Research. | ||||
Gliklich RE, Levy D, Campion DM, Leavy MB, Karl J, Berliner E, Khurana L, Hossfeld W. | ||||
Quintiles Real World and late phase research | ||||
29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Registry of Patient Registries (RoPR): Supporting Registries for Comparative Effectiveness Research | ||||
Gliklich RE, Levy D, Campion DM, Leavy MB, Karl J, Berliner E, Khurana L, Hossfeld W | ||||
Quintiles Real World and late phase research | ||||
DIA 49th Annual Meeting, Boston, MA June 2013 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Developing a Protocol for Observational Comparative Effectiveness Research. A User’s Guide | ||||
Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM | ||||
Quintiles real World and late phase research | ||||
Agency for Healthcare Research and Quality. |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2013 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Prospective observational studies to assess comparative effectiveness | ||||
Berger, ML, Dreyer N, Anderson F, Towse A, Sedrakyan A,Normand SL | ||||
Quintiles real world and late phase research | ||||
Value in Health |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2012 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Making observational studies count: shaping the future of comparative effectiveness research | ||||
Dreyer NA | ||||
Quintiles real world and late phase research | ||||
Epidemiology |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2011 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
Why observational studies should be among the tools used in comparative effectiveness research | ||||
Dreyer NA, Tunis S, Berger M, Ollendorf D, Mattox P, Gliklich RE | ||||
Quintiles real world and late phase research | ||||
Health Affairs |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2010 | English | , RWLPR (Real-World Late Phase Research-quintiles | |
GRACE Initiative. GRACE principles: recognizing high-quality observational studies of comparative effectiveness | ||||
Dreyer NA, Schneeweiss S, McNeil BJ, Berger ML, Walker AM, Ollendorf DA, Gliklich RE | ||||
Quintiles real world and late phase research | ||||
Amer J Managed Care |
||||
, Article | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment | 2010 | English | , RWLPR (Real-World Late Phase Research-quintiles | |